featured
news articles

Total number of categories

Total number of articles

Market/Novel Tech

The European Commission (EC) approves “Luxturna” (voretigene neparvovec), a recently developed gene therapy product to treat Leber congenital amaurosis (RPE65 mutations)

A commercial gene therapy company, Spark Therapeutics (NASDAQ:ONCE), announced that Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has granted marketing authorization for “Luxturna” (voretigene neparvovec), the treatment of adult and pediatric patients with vision loss due to an inherited retinal dystrophy, Leber congenital amaurosis (LCA). Spark will manufacture and supply the […]

Read full story
Featured

Visual impairment appears to be adversely associated with cognition – the Salisbury Eye Evaluation Study

Researchers from the University of Miami, in collaboration with Johns Hopkins University, demonstrate that vision loss precedes a loss of mental capacity, suggesting that maintaining eye health could protect cognition in older adults. An estimated of 5.4 million US individuals, 71 years or older, have cognitive impairment without dementia. Cognitive impairment leads to a decreased quality […]

Read full story
Research

UK and US researchers report a retinopathy associated with a dominant allele of the RGR gene

Researchers based at the UCL Institute of Ophthalmology, London and in Moorfields Eye Hospital, also in London, have shown clinical features in two pedigrees with dominantly inherited retinopathy in the “RGR” gene, encoded by a RPE-retinal G protein-coupled receptor protein. A previously reported frame-shifting mutation, c.836dupG (p.Ile280Asn*78) was identified in the terminal exon of the […]

Read full story
Introduction

December 3rd, 2018: “EURETINA-Brief”© Issue No. 183

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 3rd, 2018 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]

Read full story
Market/Novel Tech

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  CRISPR (an acronym for “clustered regularly […]

Read full story
Featured

***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***

EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH), valued at up to €2 million.  The Research Call seeks proposals from suitably qualified clinical investigators to address the current clinical uncertainty in respect of the medical management of sub-macular […]

Read full story

Latest News

Book Review